0000000000851411

AUTHOR

Enrico Garaci

showing 2 related works from this author

Need for global action for cancer control.

2008

Malemedicine.medical_specialtyCancer ResearchInternational CooperationUterine cervix cancerDiseaseGlobal HealthWorld health03 medical and health sciences0302 clinical medicineCancer controlSDG 3 - Good Health and Well-beingNeoplasmsCancer screeningmedicineGlobal healthHumans030212 general & internal medicineGynecologyHealth Services Needs and DemandCancer preventionbusiness.industryHematologyPrimary Prevention/dk/atira/pure/subjectarea/asjc/2700/2730Risk analysis (engineering)Action (philosophy)Oncology030220 oncology & carcinogenesisFemalebusiness/dk/atira/pure/subjectarea/asjc/1300/1306Annals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Thymosin α1 and α-Inteferon with Cisplatin and Etoposide in Advanced Non-Small-Cell Lung Cancer: A Phase II Study

1993

In recent years, biological response modifiers (BRMs) have emerged as an important new class of agents for treating cancer. Agents such as interferon (IFN) and interleukin 2 (IL-2) have been reported to induce significant tumor regression in various types of cancer usually resistant to chemotherapy (1,12), but their use in non-small-cell lung cancer (NSCLC) has received little attention.

CisplatinChemotherapybusiness.industrymedicine.medical_treatmentCancerLewis lung carcinomamedicine.diseaseInterferonmedicineCancer researchBiological response modifiersbusinessLung cancerEtoposidemedicine.drug
researchProduct